LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein

CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy are now standard first-line therapy for advanced HR(+)/HER2(−) breast cancer, but developing resistance is just a matter of time in these patients. Here, we report that a cyclin E1–interacting lncRNA (EILA) is up-regulated in CDK4/6i-resistant breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Zijie, Shi, Qianfeng, Li, Yudong, Jin, Liang, Li, Shunying, Wong, Lok Lam, Wang, Jingru, Jiang, Xiaoting, Zhu, Mengdi, Lin, Jinna, Wang, Qi, Yang, Wang, Liu, Yujie, Zhang, Jun, Gong, Chang, Yao, Herui, Yao, Yandan, Liu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558131/
https://www.ncbi.nlm.nih.gov/pubmed/37801505
http://dx.doi.org/10.1126/sciadv.adi3821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558131/
https://www.ncbi.nlm.nih.gov/pubmed/37801505
http://dx.doi.org/10.1126/sciadv.adi3821

Ejemplares similares